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The lysosome is a cellular signalling hub at the point of convergence of endo-
cytic and autophagic pathways, where the contents are degraded and recycled.
Pleckstrin homology domain-containing family member 1 (PLEKHM1) acts
as an adaptor to facilitate the fusion of endocytic and autophagic vesicles
with the lysosome. However, it is unclear how PLEKHM1 function at the
lysosome is controlled. Herein, we show that PLEKHM1 coprecipitates with,
and is directly phosphorylated by, mTOR. Using a phosphospecific antibody
against Ser432/S435 of PLEKHM1, we show that the same motif is a direct
target for ERK2-mediated phosphorylation in a growth factor-dependent
manner. This dual regulation of PLEKHM1 at a highly conserved region
points to a convergence of both growth factor- and amino acid-sensing path-
ways, placing PLEKHM1 at a critical juncture of cellular metabolism.
Cell growth is a tightly regulated process, which is
characterized by the balance between the synthesis and
degradation of biomolecules, such as proteins, lipids
and nucleotides. Two kinases are significant regulators
of this process and integrate amino acid (mTOR;
mechanistic target of rapamycin) and growth factor
(MAPK; mitogen-activated protein kinase) signals for
growth and survival [1,2]. Stimulation of receptor
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tyrosine kinases (RTKs) by their cognate growth fac-
tor (e.g. epidermal growth factor receptor (EGFR) by
EGF) results in dimerization of the RTK,
transautophosphorylation, activation, recruitment of
small GTPases and signal transduction through a cas-
cade of kinases [2,3]. For example, EGF stimulation of
EGFR leads to the activation of Ras GTPase, recruit-
ment and activation of RAF kinase, then MEK (MAP
kinase kinase; MKK) and then ERK 1/2 (MAPK).
Activated ERK then phosphorylates a number of
intracellular targets and simulates cellular proliferation
[2,3].
In addition to stimulating MAPK, growth factor-
mediated activation of RTKs activates the mTOR
pathway. mTOR is a serine/threonine kinase and a
catalytic subunit of two mTOR complexes – mTOR
complex 1 (mTORC1) and mTOR complex 2
(mTORC2). The two protein complexes possess differ-
ent functional properties since they interact with differ-
ent accessory proteins. Cell growth is primarily
controlled by mTORC1, whereas mTORC2 is involved
in the regulation of cell proliferation and survival and
is activated by growth factor stimulation of RTKs [1].
Both complexes share mTOR, mLST8 (mammalian
lethal with Sec13 protein 8) and Deptor (DEP-do-
main-containing mTOR-interacting protein) as sub-
units [4,5], with mTORC1 also containing Raptor
(regulatory-associated protein of mTOR) and PRAS40
(proline-rich AKT substrate of 40 kDa), as additional
subunits [6–9]. mTORC2 contains Rictor (rapamycin-
insensitive companion of mTOR), mSIN1 and Protor
[10–12].
mTOR signalling is essential for monitoring nutrient
availability in cells, and it has a central function in the
process of autophagy [1]. mTORC1 is localized to the
lysosomal surface during nutrient-rich conditions,
where it interacts with Rag GTPases through Raptor
[13]. During periods of amino acid starvation,
mTORC1 is inhibited, leading to its dissociation from
Rags, and therefore the lysosome; in contrast,
mTORC2 couples growth factor and cytokine sig-
nalling to mTORC1 functions through direct phospho-
rylation of AKT [14] and is responsive to amino acids
through the PI3K/AKT pathway [15]. mTORC1 sup-
presses autophagy flux through phosphorylation of the
ULK1 (Unc-51 like autophagy activating kinase) com-
plex that is restored upon mTOR inhibition [16,17].
Inhibition of mTORC1 leads to ULK1 activation and
subsequent activation of the autophagy pathway
through recruitment and phosphorylation of several
downstream proteins, resulting in the generation of a
double-membraned vesicle, the autophagosome [18–
22]. The autophagosome sequesters the cargo marked
for degradation and subsequently fuses with the lyso-
some where the cargo is degraded to recycle protein
and lipid components back into the cytosol, re-activat-
ing mTOR [23].
The lysosomes act as a recycling hub for proteins
and organelles, as well as a point of convergence for
endosomal and autophagy pathways. Previously, we
and others have identified that PLEKHM1 (Pleckstrin
homology domain-containing family member 1) is an
adaptor protein linking both endocytic and autophagy
pathways through its interaction with Rab7, HOPS
(homotypic fusion and vacuole protein sorting) and
Arl8b [24–27]. HOPS is a tethering complex involved
in the fusion of endocytic vesicles and is comprised of
six subunits – VPS39, VPS41, VPS11, VPS16, VPS18
and VPS33. Rab7 and Arl8b are GTPases, involved in
the transport and fusion of late endocytic/autophagy
vesicles. PLEKHM1 directly binds Rab7, facilitating
its own recruitment to the membranes [25], while its
binding to Arl8b promotes its lysosomal localization
and facilitates its interaction with HOPS complex [27].
In order to fulfil its function as an adaptor in endo-
some/lysosome pathway, PLEKHM1 requires simulta-
neous binding to both Rab7 and Arl8b [27]. However,
the regulation of PLEKHM1 function and the dynam-
ics of its intricate association with lysosomes is yet to
be understood. Various mass spectrometry screens
have reported phosphorylation sites on PLEKHM1;
however, none of them explore in depth the conse-
quences of such post-translational modification (phos-
phosite.org). Using a quantitative mass spectrometry
approach, we discovered that PLEKHM1 interacts
with mTOR and is directly phosphorylated at two pro-
line-directed serine motifs within a highly conserved
region of PLEKHM1 located between the RUN and
first PH domain. Furthermore, we demonstrate that
these sites match a MAPK consensus sequence (PxSP)
and are also direct targets for MAPK-mediated phos-
phorylation. Using a phosphospecific antibody, we
show that the inhibition of mTOR and MAPK
decreases phosphorylation of PLEKHM1 at Ser432/
Ser435. Our data suggest direct implication of mTOR
and MAPK in regulating PLEKHM1 phosphorylation,
and potentially its function, at the late endosome/lyso-
some, hinting that PLEKHM1 sits at the regulatory
crossroads of these two essential signalling pathways.
Materials and Methods
Materials
See also Table S1. cDNA, antibodies. Plasmids used in this
study are described in Table S1. PLEKHM1 point
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mutations were introduced by PCR and site-direct mutage-
nesis. GST-PLEKHM1 aa418-453 was generated by con-
ventional cloning into pGEX-4T1. DNA sequences were
verified by Sanger sequencing. The following antibodies
were used in this study: Rabbit antibodies – anti-
PLEKHM1 (in-house IG1132 [26]; and Sigma-Aldrich,
Gillingham, UK, HPA025018, for immunofluorescence);
anti-GFP (Living colors, Clontech, Takara-Bio Europe,
Saint-Germain-en-Laye, France, Cat #632460); anti-mTOR
(clone 7C10, CST, 2983S); anti-Raptor (clone 24C12, CST,
2280S); anti-Rictor (clone 53A2, CST, 2114); anti-phospho
p70S6K (T389) (CST, 9234S); anti-p70S6K (CST, 9202);
anti-phosphoserine (Millipore, Watford, UK, AB1603);
anti-phosphoPLEKHM1 S432/S435 (in-house) was gener-
ated by Immunoglobe GmbH by immunization of rabbits
using a single degenerate synthetic peptide of PLEKHM1
spanning the region 427–439 (Ac-KLVV(S/pS)(pS)P(T/pT)
(pS)PKNKC-NH2). Two rabbits were given two additional
immunizations and bled, and the final phospho-PLEKHM1
(Ser432/Ser435; IG-1364) was purified against columns of
dephosphorylated peptide and also single phospho-entities
(PS432 and pS435 separately), anti-phosphoERK1/2 (T-
202/Y204) (CST, 4370); anti-ERK1/2 (CST, 4695); anti-
mLST8 (GbL; CST, 3274); anti-VPS41 (Santa Cruz, sc-
377118); antivinculin (Sigma-Aldrich, V4505); anti-LAMP2
(clone H4B4; DSHB); anti-GST (Sigma-Aldrich, G1160);
anti-HA (Roche, 11867423001); and anti-LAMP2 (DSHB,
ABL-93-c). Secondary HRP-conjugated antibodies, goat
anti-rabbit and goat anti-mouse, were used for
immunoblotting. Alexa-conjugated 647 (mouse) and Alexa-
555 rabbit secondaries were used for immunofluorescence
studies (Invitrogen).
Cell culture
HeLa Kyoto [52] and U2OS cells were obtained from
ATCC and grown in full medium (DMEM supplemented
with 10% foetal bovine serum, 1% non-essential amino
acids, 1% sodium pyruvate and penicillin/streptomycin).
HeLa FlpIn-TREx PLEKHM1-GFP cells were previously
described [26]. Protein expression was induced by
1 µgmL1 doxycycline. U2OS cells with endogenous GFP-
PLEKHM1 were generated using CRISPR/Cas9-mediated
modification of human PLEKHM1 (NM_014798.3) using
the Cas9 D10A ‘nickase’ mutant. Optimal sgRNA pairs
were identified and chosen on the basis of being as close as
possible to the point of GFP insertion while having a low
combined off-targeting score (sgRNA 1 50-GATGACACC
TGAAGAGACAGA-30 and sgRNA2 50-TACTTGCTG
CACCACTACTTAGG-30). The antisense guide (sgRNA2)
was cloned onto the spCas9 D10A expressing pX335 vector
(Addgene plasmid no. 42335) and the sense guides
(sgRNA1) into the puromycin-selectable pBABED P U6
plasmid (Dundee-modified version of pBABE-puro plas-
mid). A donor construct consisting of GFP flanked by
approximately 500-bp homology arms was synthesized by
GeneArt (Invitrogen, Life Technologies, Paisley UK); each
donor was engineered to contain sufficient silent mutations
to prevent recognition and cleavage by Cas9 nuclease. The
U2OS cells were transfected with both sgRNA and donor
constructs and selected in 1 lgmL1 puromycin for 48 h,
retransfected and allowed to recover in puromycin-free full
medium. When confluent, cells were single-cell sorted for
GFP-positive populations and homozygous clones selected
for further analysis. MEFs expressing HA-PLEKHM1 were
generated through retro-viral transduction with MSCV-N-
Flag-HA-IRES-PURO-PLEKHM1-WT and selected using
2 µgmL1 puromycin. Where indicated, cells were incu-
bated in Earle’s balanced salt solution (EBSS) medium to
induce amino acid starvation; or treated with Bafilomycin
A1 (200 nm) or chloroquine (20 µm) to block fusion with
lysosomes; torin 1 (250 µm) or Ku-0063794 (10 µm) (both
from Tocris) to inhibit mTOR activity; or U0126 (10 µm)
(Promega, Southampton, UK) to inhibit MAP kinases, for
the time indicated in the figure legends. Transient transfec-
tion of HeLa cells was performed using TurboFect, accord-
ing to the manufacturer’s instructions.
Immunoprecipitation
Cells were lysed in CHAPS lysis buffer (50 mm Tris/HCl
[pH 7.5], 0.5% CHAPS, 115 mm NaCl and 5 mm MgCl2)
supplemented with EDTA-free protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail (Sigma).
Lysates were cleared by centrifugation, and the clear super-
natant was incubated with primary antibody, rotating over-
night at 4°C, followed by incubation with protein A
sepharose beads (1 h with rotation at 4 °C), for endoge-
nous immunoprecipitation, or with either GFP-TRAP
beads (ChromoTek GmbH, Martinsried, Germany) or HA-
affinity matrix (Sigma) for 30 min, rotating at 4°C. Pellets
were washed three times with lysis buffer and four times
with wash buffer (50 mM Tris/HCl [pH 7.4], 150 mM NaCl,
2 mM MgCl2 and 0.1% Triton X-100). Proteins were eluted
in 2x Laemmli sample buffer and subjected to SDS/PAGE
and western blotting.
Western blotting
CHAPS (50 mm Tris/HCl [pH 7.5], 0.5% CHAPS,
115 mm NaCl, and 5 mm MgCl2) or total cell lysis buffer
(50 mm Tris/HCl [pH 7.4], 5 mm MgCl2, 150 mm NaCl,
1% SDS), supplemented with EDTA-free protease inhibitor
cocktail (Roche) and phosphatase inhibitor cocktail
(Sigma), was used for cell lysis. Phosphatase inhibitors were
omitted from samples treated with lambda-phosphatase.
Lysates were cleared by centrifugation. For dephosphoryla-
tion of PLEKHM1, either whole cell lysates or PLEKHM1
immunoprecipitated on GFP-TRAP beads were incubated
with 1 µL of lambda-phosphatase (NEB) with the
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accompanying manufacturer’s 10x phosphatase buffer and
1 mM MnCl2, for 30 min at 30 °C. 2x Laemmli sample buf-
fer was added to samples to stop the reaction. Proteins
were resolved in 7% polyacrylamide gels or 5% polyacry-
lamide containing 20 µM Phos-Tag (Nard) and 10 mM
MnCl2, for protein mobility shifts. The proteins were then
transferred onto a 0.2-µm PVDF membrane (Merck Milli-
pore). Following incubation with primary and secondary
antibodies, the blots were developed by ImmunoCRUZ
western blotting Luminol reagent (Santa Cruz). Quantifica-
tion was performed with FIJI/IMAGEJ software.
Mass spectrometry
Sample preparation for mass spectrometry
For testing of interaction partners, PLEKHM1-GFP was
immunoprecipitated in HeLa FlpIn-TREx PLEKHM1-
GFP cells on GFP-TRAP beads. Additionally, for detec-
tion of phosphorylation sites, SILAC labelling was used.
HeLa FlpIn-TREx PLEKHM1-GFP cells were cultured in
DMEM supplemented with either L-arginine 12C6
14N4
(Arg0) and L-lysine12C6




15N2 (Lys8) as previously
described (Ong et al., 2002). SILAC-labelled cells were
lysed in CHAPS lysis buffer. PLEKHM1-GFP expression
was induced for 16h with doxycycline, and HeLa FlpIn-
TREx cells, cultured in light SILAC-labelled medium, were
treated in EBSS for 4 h to starve cells of amino acids.
PLEKHM1-GFP was immunoprecipitated using GFP-
TRAP, and eluates were mixed 1:1 (v/v) and run on an
SDS/PAGE gel. After excision of individual gel bands and
destaining according to manufacturer´s instructions, pro-
teins were reduced with 10mM DTT for 45 min at 56 °C
and alkylated with 55mM Iodoacetamide for 30 min at RT
under light protection. After digestion with Trypsin at
37 °C overnight, tryptic peptides were extracted from the
gel pieces consecutively with 30% acetonitrile (ACN) con-
taining 3% trifluoroacetic acid (TFA), then 80% ACN con-
taining 0.1% TFA and finally 100% ACN for 30 min each.
Extraction solutions were combined and dried by vacuum
centrifugation before reconstitution in 0.1% formic acid for
LC-MS/MS analysis.
LC-MS analyses
Peptides were analysed on an Orbitrap Elite mass spectrom-
eter coupled to an easy nLC II (Thermo Fisher Scientific,
Paisley, UK) using a 20 cm long, 75 µm ID fused-silica col-
umn, which has been packed in house with 3 µm C18 parti-
cles (ReproSil-Pur, Dr. Maisch), and kept at 45°C using an
integrated column oven (Sonation). Peptides were eluted by
a non-linear gradient from 8–40% acetonitrile over 240 min
and directly sprayed into the mass spectrometer via a nano-
Flex ion source (Thermo Fisher Scientific) at a spray
voltage of 2.3 kV. Full scan MS spectra (300–2000 m/z)
were acquired at a resolution of 120,000 at m/z 200, a maxi-
mum injection time of 100 ms and an AGC target value of
1 9 106 charges. Up to 20 most intense peptides per full
scan were isolated in the ion-trap using a 2 Th window and
fragmented using collision-induced dissociation (CID, nor-
malized collision energy of 35). MS/MS spectra were
acquired in rapid mode using a maximum injection time of
25 ms and an AGC target value of 5 x 103. Ions with charge
states of 1 and > 6 as well as ions with unassigned charge
states were not considered for fragmentation. Dynamic
exclusion settings were 1 repeat count and 30-s repeat dura-
tion as well as an exclusion duration of 90s in order to mini-
mize repeated sequencing of already acquired precursors.
Mass spectrometry data processing
Mass spectrometry raw data processing was performed with
MaxQuant (v 1.3.0.5) applying default parameters.
Acquired spectra were searched against the human refer-
ence proteome (Taxonomy ID 9606) downloaded from
UniProt (09-2012) and a collection of common contami-
nants (244 entries) using the Andromeda search engine inte-
grated in MaxQuant [53,54]. Identifications were filtered to
obtain false discovery rates (FDR) below 1% for both pep-
tide spectrum matches (PSM; minimum length of 7 amino
acids) and proteins using a target-decoy strategy [55]. See
Data S1 for analysis. Raw data are available via Pro-
teomeXchange with identifier PXD021199.
Confocal microscopy
U2OS cells endogenously expressing GFP-PLEKHM1 were
seeded on glass coverslips and, on the following day,
starved in EBSS or treated with Bafilomycin A1 for the
time periods indicated in the figure legends. Cells were then
fixed in 4% paraformaldehyde (PFA; Santa Cruz, 30525-
89-4) for 12 min minimum. Cells were permeabilized with
0.1% saponin in PBS at room temperature, followed by
incubation with the primary antibodies in 0.1% saponin/
5% BSA (bovine serum albumin)/PBS (phosphate-buffered
saline). The coverslips were washed three times in 0.1%
saponin/PBS, before being incubated with the secondary
antibodies and DAPI (Molecular Probes, Lifetechnologies,
Paisley, UK) for 1 h in 0.1% saponin/5% BSA/PBS. For
detection of endogenous GFP-PLEKHM1, nanobody
boosters towards GFP (anti-GFP, Atto-488 coupled, Chro-
motek; gba488-100) were used to enhance the signal. After
incubation in secondary antibodies, the coverslips were
washed twice in PBS/0.1% saponin, once in PBS and once
in ddH2O to remove residual saponin prior to mounting in
ProLong Diamond Antifade containing Mowiol (Invitro-
gen, p36965). Cells were imaged using a Zeiss 710 confocal
microscope with a 63 9 objective lens. Subsequent image
analysis was performed using FIJI/IMAGEJ [56].
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Protein expression and purification
GST-PLEKHM1 aa418-453 was cloned into pGEX-4T-1
(GE Healthcare) and expressed in E. coli BL21 (DE3) cells
in LB medium. Expression was induced by addition of
0.5 mM IPTG, and, subsequently, cells were incubated at
16°C overnight. Harvested cells were lysed using sonica-
tion in a lysis buffer (20 mM Tris/HCl [pH 7.5], 10 mM
EDTA, 5 mM EGTA, 150mM NaCl), and the supernatant
was subsequently applied to Glutathione Sepharose 4B
beads (GE Healthcare, Hatfield, UK). After several
washes, fusion protein-bound beads were used directly in
the kinase assay.
In vitro kinase assay
Purified GST-tagged PLEKHM1 (aa 418-453) was washed
3 times in kinase buffer (10 mM HEPES, [pH 7.5], 50 mM
NaCl, 50 mM b-glycerophosphate, 1 mM dithiothreitol
[DTT], 10 mM MgCl2, 4 mM MnCl2) and subsequently
incubated with 300 ng of a catalytic fragment (spanning
amino acids 1362 to 2549) of human mTOR kinase (40061;
BPS Bioscience) in the presence or absence of ATP
(100 lM) for 1 h at 30 °C. 250 nM torin 1 was used to inhi-
bit the in vitro kinase activity. For MAPK in vitro assay,
ERK2 WT or kinase dead (D168A) (10 ng/100 µL reac-
tion) was activated by incubating with MEK (10 ng/100 µL
reaction) in kinase buffer (100 mM NaCl, 50 mM Tris/HCl,
pH 7.0, 10 mM MgCl2, 100 mM ATP and 0.1% bovine
serum albumin) for 30 min at 30° C. Recombinant GST-
PLEKHM1 was added with additional cold ATP (100 µM),
and the reaction was continued for 30 min at room temper-
ature. After incubation, the reaction was stopped by adding
2x Laemmli buffer and by boiling at 95 °C for 5 min prior
to SDS/PAGE and western blot analysis.
Statistical analysis
Results were plotted and analysed using GraphPad Prism
software using the statistical method outlined in the figure
legends.
Results
PLEKHM1 is found in complex with mTOR
Previously, we identified PLEKHM1 as an interac-
tion partner of Rab7 [25] and subsequently showed
that PLEKHM1 is present on LAMP1/LAMP2/
Rab7-positive vesicles, which facilitates the fusion of
autophagosomes and lysosomes [26] and influences the
Salmonella-containing vacuole (SCV) formation [25].
As PLEKHM1 localizes at the lysosomal compartment
through its interaction with Rab7 [27], we performed
mass spectrometry analysis of the PLEKHM1 interac-
tome using a Zwitter-ionic buffer (CHAPS) that
enriches membrane-bound proteins, to gain a better
understanding of the role of PLEKHM1 in this com-
partment. We performed SILAC-based LC-MS-MS on
trypsinized immunoprecipitated complexes derived
from HeLa-TREX cells expressing WT PLEKHM1-
GFP (HEAVY) under doxycycline control for induci-
ble expression and compared the interactome to un-in-
duced cells (LIGHT). Using this method, we detected
a number of late endocytic and lysosome-associated
proteins (Fig. 1A), including Rab7, LAMP1 and
LAMP2, in addition to HOPS complex and multiple
SNAREs (Fig. 1A) [25,26]. These were found readily
in our interactome and served as validation of the
assay (Fig. 1A). Given our interest in the regulation of
PLEKHM1 and the quantitative nature of LC-MS-
MS, we observed a distinct subset of interaction part-
ners of which mammalian target of rapamycin
(mTOR) was one of the most abundant. Using the
number of unique peptides detected (arrow thickness
Fig. 1A), we pinpointed a strong interaction between
mTOR and PLEKHM1 (Fig. 1A). As mTOR is
known to localize to lysosomes and regulate autop-
hagy [1], we focused our studies on components of the
mTOR signalling pathway. We were able to identify
components of the mTORC1 complex (Raptor),
Fig. 1. (A) Schematic representation of a subset of PLEKHM1 interacting partners as detected by mass spectrometry following
immunoprecipitation of PLEKHM1-GFP using GFP-trap. The arrow thickness is proportional to the number of unique peptides detected by
mass spectrometry. (B) HeLa FlpIn TREx cells stably expressing PLEKHM1-GFP were stimulated with 1 µgmL1 doxycycline 24 h before
lysis. The cells were lysed in CHAPS buffer and subjected to GFP-trap co-immunoprecipitation, followed by SDS/PAGE and western blotting
and probed with the indicated antibodies. Blots are representative of n = 3 independent experiments. (C) Representative confocal
micrographs of CRISPR/Cas9-modified U2OS cells that express N-terminally GFP-tagged endogenous PLEKHM1 (GFP-PLEKHM1). Cells
were either treated with full medium plus DMSO (FM) or Bafilomycin A1 (200nM) for 4 h to enlarge LAMP2-positive lysosomes. Cells were
then fixed and counterstained with DAPI (blue; DNA), LAMP2 (magenta) and mTOR (red) and GFP-PLEKHM1 (green). Scale bar 10 µm. (D)
Representative confocal micrographs of PLEKHM1-GFP HeLa FlpIn TREx cells that were left untreated (Full medium, FM, upper panels) or
placed in complete starvation medium (starved) for 4 h before staining with LAMP2 (magenta) and mTOR (red) and visualization by confocal
microscope. White box shows area of interest. Scale bar 10 µm. (E) Quantification of either mTOR/PLEKHM1 colocalization (red circles) or
LAMP2/PLEKHM1 colocalization (blue squares) under either full media (FM) or starvation (starve) conditions. Mean  SD of n = 3
independent experiments. ****P < 0.0001 Paired Student’s t-test.
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mTORC1 regulatory GTPases (Rheb, RagA/B),
mTORC2 complex (Rictor, Protor), Ragulator (Lam-
tor1, Lamtor2), Gator1 (NPLR3) and Gator2 com-
plex (MIOS, SEH1L, WDR59, SEC13), as well as the
constitutive mTOR interaction partner mLST8
(Fig. 1A). PLEKHM1-GFP could coprecipitate with
mTOR, Raptor, Rictor, mLST8 and VPS41 in doxy-
cycline-induced HeLa-TREX cells, but not in un-in-
duced immunoprecipitates (Fig. 1B). Using CRISPR/
Cas9, we generated endogenous GFP-tagged
PLEKHM1 (Fig. S1A) and could observe PLEKHM1
colocalizing with mTOR- on LAMP2-positive lyso-
somes (Fig. 1C, upper panels) that were enlarged
upon Bafilomycin A1 treatment (V-ATPase inhibitor;
Fig. 1C lower panels). Under nutrient-rich (full med-
ium) conditions, we observed PLEKHM1-GFP
(green) localized on LAMP2- (magenta) and mTOR-
(red) positive vesicles (Fig. 1D upper panels and
quantified in Fig. 1E). Upon amino acid starvation,
PLEKHM1 was retained on LAMP2-positive vesicles,
but mTOR became dispersed and reduced colocaliza-
tion with PLEKHM1-GFP (Fig. 1D, lower panels,
insets and quantified in Fig. 1E). Thus, PLEKHM1-
GFP localizes and interacts with mTOR on the lyso-
some. Given the previously reported role of
PLEKHM1 in facilitating the fusion of late endo-
somes and autophagosomes with the lysosome [25,26],
we hypothesized that mTOR phosphorylates and
potentially regulates PLEKHM1 at the lysosome to
control its function.
mTOR directly phosphorylates PLEKHM1 at a
conserved serine motif
mTOR is a key regulator of cellular metabolism, plays
a key role in amino acid sensing at the lysosome and
acts as one of the main ‘on/off’ switches for the autop-
hagy pathway [16,17]. Therefore, we next asked
whether PLEKHM1 is phosphorylated in an mTOR-
dependent manner. To inhibit mTOR, we used either
torin 1, or Ku-0063794, both of which are highly
specific towards mTOR, and do not affect PI3K activ-
ity at the concentrations used [28,29]. Upon either
mTOR inhibition with Ku-0063794 (KU) or starvation
(EBSS) conditions, we could observe increased mobil-
ity shift of endogenous PLEKHM1, compared to full
medium controls (Fig. 2A). After a period (4 h) of
starvation and refeeding for 40 min in full medium,
this increased mobility shift was reversed (Fig. 2A),
implying that under these conditions PLEKHM1 may
be post-translationally modified. Immunoprecipitation
of endogenous PLEKHM1 and subsequent treatment
with lambda-phosphatase (k-PPase) resulted in
increased mobility of the immunoprecipitated
PLEKHM1 (Fig. 2B). Next, HeLa FlpIn-TREx cells
were induced for 16 h overnight with doxycycline
to express PLEKHM1-GFP and were treated for
increasing time in starvation medium. The cells were
subsequently lysed and run on a phos-tag gel. The
inclusion of the phos-tag chelating agent in conven-
tional polyacrylamide gels retards the migration of
Fig. 2. (A) Mouse embryonic fibroblasts (MEFs) were placed into either full medium (FM), full medium containing 10 µm Ku-0063794 (KU)
for 4 h or EBSS medium (starved) for 4 h or EBSS for 4 hours followed by FM for 40 min. Cells were lysed and analysed by western
blotting. Samples were blotted for endogenous Plekhm1, and anti-vinculin was used as a loading control. (B) Endogenous PLEKHM1 was
immunoprecipitated from MEFs and either left untreated or treated with lambda-phosphatase (k-PPase) for 30 min. Blots were probed with
anti-PLEKHM1. (C) HeLa FlpIn TREx cells stably expressing PLEKHM1-GFP were stimulated by 1 mgmL1 doxycycline for 16 hours and
either left untreated or treated for the times indicated with starvation media (EBSS). In addition, untreated lysate was treated with lambda-
phosphatase (k-PPase) for 30 mins. Total cell lysates were then run on either a 5% gel containing phos-tag (20 µM) or a 7% polyacrylamide
gel and probed for the presence of PLEKHM1 and vinculin as a loading control. (D) HeLa FlpIn TREx cell stably expressing PLEKHM1-GFP
was stimulated by 1 µgmL1 doxycycline for 16 h. The cells were then either left untreated, treated with phosphatase or starved for 20, 50
or 120 min, before being lysed in CHAPS lysis buffer and subjected to GFP-Trap Co-IP and western blotting. Blots are representative of
n = 3 independent experiments. (E) Phosphorylated PLEKHM1 was calculated as a percentage of total PLEKHM1-GFP on the beads.
*P < 0.026; ns = not significant, Student’s t-test of n = 3 independent experiments. (F) HeLa FlpIn TREx cells stably expressing PLEKHM1-
GFP were either left un-induced or stimulated by 1 µgmL1 doxycycline for 16 h and then treated with either DMSO, 10 µM Ku-0063794
(KU) or 10 µM Ku-0063794 (KU) plus 20 µM chloroquine (CQ) for 4 h. Cells were then lysed in CHAPS buffer, and anti-GFP-Trap beads were
used to immunoprecipitate GFP-tagged PLEKHM1. An untreated IP was treated with lambda-phosphatase for 30 mins as control. Samples
were then subjected to SDS/PAGE and analysed by western blotting using the indicated antibodies. Numbers shown indicate the
percentage of phosphorylated PLEKHM1 or immunoprecipitated sample (mTOR, VPS41) compared with input or total IP. (G) The workflow
for identification of PLEKHM1 phosphorylation sites by using SILAC-based mass spectrometry. (H) Schematic diagram showing the
phosphosites identified that overlapped between starvation and Ku-0063794 treatments. Alignment of multiple species of PLEKHM1 in the
region of Ser432/Ser435 (human PLEKHM1) shows the high degree of sequence conservation. (I) The mass spectrometric fragment ion
scan of the peptide corresponding to phosphorylated Ser432 and Ser435 in LVVSSPTSPK
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phosphorylated protein species and can help distin-
guish different states of phosphorylation of the protein
of interest [30]. Phosphatase-treated PLEKHM1-GFP
sample showed a large increase in mobility, and
increasing time of mTOR inhibition showed a range of
mobility shifts between the untreated (full medium)
and phosphatase-treated (Fig. 2C). This indicates that
PLEKHM1-GFP phosphorylation is decreased upon
mTOR inhibition (Fig. 2C). Next, we induced
PLEKHM1-GFP expression in HeLa-TREX cells and
left the cells untreated or starved them of amino acids
and growth factors for up to 2 h (starve). Using GFP-
trap beads, we immunoprecipitated PLEKHM1-GFP
and probed with a generic phosphoserine antibody
and monitored the effect on PLEKHM1 phosphoryla-
tion. As a negative control, we treated immunoprecipi-
tated PLEKHM1 for 30 min using k-PPase to
dephosphorylate PLEKHM1. Increased time in starva-
tion medium resulted in decreased PLEKHM1 phos-
phorylation up to approximately 70% of total
phosphorylated PLEKHM1 after 2 h of starvation
(Fig. 2D and quantified in 2E). PLEKHM1 phospho-
rylation (using phosphoserine antibody) was decreased
by almost 70% after treatment with 10 µM Ku-
0063794 for 4 h (Fig. 2F). This was associated with
decreased mTOR association with PLEKHM1 under
these conditions (~60% loss of mTOR; Fig. 2F) that
was not prevented by lysosome inhibition (chloro-
quine, CQ; Fig. 2F). The majority of VPS41 (HOPS
complex) was still bound to PLEKHM1 under these
conditions (~ 70% bound; Fig 2F). Next, we wanted
to map potential PLEKHM1 phosphorylation sites
that changed upon amino acid starvation and mTOR
inhibition. Using SILAC (stable isotope labelling of
amino acids in cell culture), to differentiate changes in
phosphorylation status of PLEKHM1, we labelled
doxycycline-induced PLEKHM1-WT cells with either
LIGHT or HEAVY amino acids, and either starved
(LIGHT) the cells or left them in full medium
(HEAVY) for 2 h. We also compared the phosphory-
lation status of PLEKHM1-GFP in untreated (full
medium + DMSO) versus KU-treated cells. We
immunoprecipitated PLEKHM1-GFP using GFP-Trap
beads and analysed by LC/MS to map-specific amino
acid residues on PLEKHM1 that change upon amino
acid depletion/KU treatment (Fig. 2G). In total, we
mapped nine potential phosphorylation sites that
decreased upon starvation or KU treatment. Of these
sites, only Ser280, Ser305, Ser432, Thr434, Ser435 and
Ser501 (Fig. S1B–G) overlapped between the two con-
ditions (Starved and KU). Of particular interest were
the clusters of phosphoserine/threonine around 431-
435 on PLEKHM1 (Fig. 2H,I). These sites have also
previously been found to be enriched in multiple inde-
pendent mass spectrometry analyses (phosphosite.org).
These include analysis of the ultradeep human phos-
phoproteome [31] and were found to be increased in a
number of cancer cell types including breast cancer
[32], non-small-cell lung cancer [33] and leukaemia
[34]. Interestingly, Ser432/435 was shown to decrease
upon rapamycin treatment [35], and the same sites
have also been shown to be increased upon insulin
treatment [36]. Therefore, due to the number of hits at
these sites and due to the fact that this cluster of phos-
phoserine residues is present within a highly conserved
region of PLEKHM1 (Fig. 2H; alignment), we wanted
to verify that these were indeed mTOR-directed phos-
phorylation sites on PLEKHM1.
Fig. 3. HeLa cells transiently expressing PLEKHM1-GFP WT or PLEKHM1-GFP S432A/S435A were treated with EBSS for 4 h or left
untreated and analysed by western blotting using the phosphospecific antibody against hPLEKHM1 S432/S435, GFP and phospho-p70S6K
antibodies. Blots are representative of n = 3 independent experiments. (A) HeLa FlpIn TREx cells stably expressing PLEKHM1-GFP were
either left un-induced or stimulated by 1 µgmL1 doxycycline for 16 h and then treated with either DMSO, 10 µM Ku-0063794 (KU), 250 nM
torin 1 or starved for 4 h in EBSS medium. HeLa cells were transiently transfected with either PLEKHM1-GFP WT or PLEKHM1-GFP
S432A/S435A as controls. Total cell lysates were then subjected to SDS/PAGE, and antibodies against phosphorylated PLEKHM1 (S432/
S435), GFP (total PLEKHM1) and phospho-p70S6K (T389) were used. Blots are representative of n = 3 independent experiments. (B) MEFs
stably expressing HA-PLEKHM1 (human) were either left in full medium (FM) or starved for 4 h in EBSS medium and lysed, and anti-HA
was used to immunoprecipitate PLEKHM1. Samples were analysed using SDS/PAGE and western blotting for phospho-PLEKHM1(S432/
S435) and anti-HA. Rabbit IgG was used as a control for immunoprecipitation. (C) Endogenous PLEKHM1 was immunoprecipitated from
HeLa cells grown in either full medium (FM) or EBSS (4 h). Samples were then subjected to SDS/PAGE and western blotting and probed
with phospho-PLEKHM1(S432/S435) and total PLEKHM1 antibodies. Levels of phospho-PLEKHM1 were calculated as a percentage and
were normalized to total immunoprecipitated PLEKHM1 in each lane. Rabbit IgG was used as negative control for immunoprecipitation.
Blots are representative of n = 3 independent experiments. (D) In vitro kinase assay using purified mTOR kinase and purified GST-
PLEKHM1 418-453 fragment in the presence or absence of ATP. Blots are representative of n = 3 independent experiments. (E) U2OS cells
overexpressing PLEKHM1-GFP WT (upper panels) or S432A/S435A (lower panels) were counterstained with anti-phospho-PLEKHM1 pS432/
pS435 (red), anti-LAMP2 (magenta) and DAPI. Scale bar 10 µm.
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PLEKHM1 is directly phosphorylated by mTOR
Next, we developed phosphospecific antibodies direc-
ted against a dual phosphorylated peptide of
PLEKHM1 containing phosphorylated Ser432/Ser435.
Upon transient transfection of the PLEKHM1 WT
and Ser432A/Ser435A (2A) plasmids, we could show
that the phosphospecific antibody only recognized
phosphorylated PLEKHM1-WT and not the
PLEKHM1 protein in which Ser432/Ser435 sites are
mutated to alanine (Fig. 3A). Moreover, phosphoryla-
tion of PLEKHM1 at these sites decreased upon
amino acid starvation in HeLa FlpIn-TREx cells over-
expressing PLEKHM1-GFP (Fig. 3A), and phospho-
rylation at these sites was sensitive to torin 1, Ku-
0063794 and amino acid starvation (Fig. 3B). We were
also able to detect phosphorylated PLEKHM1 that
was sensitive to amino acid starvation using mouse
embryonic fibroblasts expressing HA-tagged
PLEKHM1 (Fig. 3C). Importantly, we could detect
endogenous levels of phosphorylated Ser432/435
PLEKHM1 in HeLa cells that was sensitive to amino
acid starvation (Fig. 3D). Using bacterially purified
GST-PLEKHM1 (amino acids 418-453) that contains
the potential mTOR phosphorylation sites, we showed
that purified mTOR can phosphorylate Ser432/435
in vitro as phosphorylation (as detected by pS432/
pS435 antibody) was sensitive to the presence of ATP
and torin 1 (Fig. 3E). Overexpression of WT
PLEKHM1-GFP showed that PLEKHM1 is phospho-
rylated at S432/S435 on LAMP2-positive vesicles
(lysosomes; (Fig. 3F, upper panels) and pS432/pS435
is lost when these sites are mutated (Fig. 3F, lower
panels). Next, we wanted to test whether mutation of
these phosphosites affected the previously identified
interactions of PLEKHM1 [25,26,37]. We tested the
interaction of overexpressed HA-tagged PLEKHM1
WT, 2A or 2D (S432D/S435D) with either GFP alone,
GFP-Rab7 (Fig. S2 A-B) or GFP-GABARAP (Fig S2
C-D). Interestingly, neither mutant significantly
affected the interaction of PLEKHM1 with either
Rab7 or GABARAP. Moreover, overexpression of
PLEKHM1-WT, 2A or 2D mutants did not have a
dominant effect on LC3B lipidation or p62/SQSTM1
turnover, when overexpressed in HEK293T cells
(Fig. S2E-G). Taken together, we show that the
Ser432/435 sites are phosphorylated by mTOR are sen-
sitive to conditions that alter mTOR activity and have
an, as yet, undefined effect on PLEKHM1 function.
PLEKHM1 Ser432/Ser435 is MAPK target sites
The sites we identified as being phosphorylated by
mTOR conform to the proline-directed mTOR consen-
sus motif [38]. When we further inspected the phos-
phomotif within PLEKMH1, we realized that the
same sites also conform to the PxSP MAPK-directed
phosphorylation motif (Fig. 4A) [39,40]. This
prompted us to explore whether these sites were also
possible substrates of the MAPK pathway. Therefore,
we tested whether PLEKHM1 phosphorylation could
be induced in a growth factor/MAPK-dependent man-
ner. MEFs expressing either vector only or HA-tagged
PLEKHM1 were grown in 1% serum-containing med-
ium for 16 h and subsequently stimulated with either
full medium (FM) or with 50 ng/mL epidermal growth
factor (EGF) for 0, 30, 60, 120 and 180 min. In the
latter case, PLEKHM1 phosphorylation peak coin-
cided with the peak in the activation of the MAPK
Fig. 4. (A) Schematic representation of identified PLEKHM1 phosphorylation sites that align to the proline-directed mTOR phosphorylation
motif and PxSP MAPK phosphorylation motif. Inhibitors of both pathways are shown to distinguish the potential differences in
phosphorylation. (B) MEFs overexpressing vector only or HA-PLEKHM1 were grown overnight in medium containing 1% serum and,
subsequently, cultured in either full medium or FM containing 50 ngmL1 EGF. Cells were treated for the indicated times, and western
blots were performed on total cell lysates using the indicated antibodies. (C) In vitro kinase assay using purified His-GST-tagged MEK
(MKK1), GST-tagged-ERK2 (MAPK1) WT and -ERK2 kinase dead (D168A) using purified GST-PLEKHM1 418-453 fragment as substate in the
presence or absence of ATP. Samples were probed with phospho-PLEKHM1(S432/S435), GST (ERK2), anti-His tag (MEK) and total
PLEKHM1 input detected by ponceau S Blots are representative of n = 3 independent experiments. (D) MEFs overexpressing HA-tagged
PLEKHM1 were grown overnight in medium containing 1% serum and subsequently cultured in medium containing 50 ngmL1 of the
indicated growth factors (EGF, FGF, PDGF-AA/BB, IGF) with or without 10 µM U0126 or 250nM torin 1 for 30 min. For those cells treated
with U0126 or torin 1, cells were preincubated for 1 h prior to growth factor treatment. Western blots were performed on total cell lysates
using the indicated antibodies. (E) Representative western blots of MEFs expressing empty vector (V) or HA-tagged PLEKHM1 were grown
in full medium (FM; DMEM) or FM plus 250 nM torin 1, 10 µM U0126 (UO) or 250 nM torin 1 plus 10 µM U0126 or EBSS. Total cell lysates
were subjected to SDS/PAGE western blotting and probed with the indicated antibodies. (F) Quantification of (E). Percentages are
calculated based on total versus phospho-PLEKHM1 (S432/S435). Horizontal bar represents mean  SEM of n = 3 independent
experiments (individual points on graph). One-way ANOVA statistical test. **P = 0.0050; ***P = 0.0006; ****P ≤ 0.0001; *P = 0.0336 (torin
1 vs torin 1 + U0126); *P = 0.0253 (U0126 vs torin 1 + U0126).
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pathway, as reflected in the levels of phosphorylated
ERK (phospho-ERK1/2) after a 30-minute stimulation
(Fig. 4B). As the sites conformed to the MAPK con-
sensus sequence and phosphorylation of PLEKHM1
followed that of ERK1/2 activation (Fig. 4B), we next
tested whether PLEKHM1 could be directly phospho-
rylated by MAPK1 (ERK2). Using GST-PLEKHM1
(418-456, Fig. 3F), we incubated recombinant MKK1
(MEK) alone, MAPK1 WT alone, MKK plus
MAPK1 and MKK1 plus kinase dead MAPK1
(D168A), in the presence or absence of ATP. Under
these conditions, PLEKHM1 is directly phosphory-
lated by MAPK1 at Ser432/Ser435 only in the pres-
ence of ATP (Fig. 4C, lanes 3 and 5), but not by
MKK1 alone (Fig. 4C, lane 1) or by kinase dead
MAPK (Fig. 4C, lanes 6 and 7). Next, we wanted to
test the specificity of such response by applying a num-
ber of different growth factor conditions in combina-
tion with the inhibition of MAPK and mTOR
pathways and subsequently probing the levels of phos-
phorylated PLEKHM1 at the phosphospecific sites.
MEFs expressing HA-tagged PLEKHM1 were grown
overnight in 1% serum and stimulated in the presence
or absence of 10 µM U0126 or 250 nM torin 1 with
either EGF (epidermal growth factor), FGF2 (fibrob-
last growth factor 2), IGF-1 (Insulin-like growth factor
1), PDGF-AA (Platelet-derived growth factor-AA),
PDGF-BB or PDGF-AB for 30 min. Using phospho-
ERK1/2 (Thr202/Tyr204) and phospho-p70S6K
(T389), as a read-out MAPK and mTOR activity,
respectively, we observed a robust phosphorylation
(>2-fold increase in phospho-PLEKHM1 compared
with unstimulated) of PLEKHM1 at Ser432/435 trea-
ted with EGF, FGF2 and PDGF-AB (Fig. 4D).
FGF2-mediated PLEKHM1 phosphorylation was par-
tially (approx. 40%) sensitive to MAPK inhibition,
but not to mTOR inhibition (Figs 4D and S3). Next,
we wanted to assess the relative contributions of the
mTOR and MAPK pathways to Ser432/Ser435 phos-
phorylation. Stimulation of MEFs containing HA-
PLEKHM1 with full medium resulted in a robust
phosphorylation at Ser432/Ser435, while treatment
with the mTOR inhibitor torin 1 resulted in an
approximate 50% decrease (Fig. 4E, F). Treatment
with U0126 resulted in a 60% decrease, and inhibition
of both MAPK and mTOR resulted in an almost com-
plete loss of PLEKHM1 phosphorylation, similar to
that observed after a 4-h starvation (EBSS medium;
Fig. 4E, F). This indicates that both the mTOR and
the MAPK pathways can phosphorylate directly
PLEKHM1 at Ser432/Ser435, pointing to a conver-
gence of pathways for a function that has yet to be
determined.
Discussion
The late endocytic adaptor protein PLEKHM1, which
is involved in osteoclast vesicle transport [41] through
an interaction with Rab7 [24–26], plays an important
role in the maturation of late endosomes [24,26,27],
biogenesis of the Salmonella-containing vacuole [25]
and fusion of autophagosomes and lysosomes
[26,37,42]. How these distinct, yet related, functions are
regulated was unclear. Herein, we discover post-trans-
lational modification of human PLEKHM1 in a highly
conserved region spanning amino acids 420–450. Phos-
phorylation of serine residues in a proline-directed
manner is carried out directly by mTOR kinase, a bind-
ing partner of PLEKHM1. Interestingly, it has recently
been shown that mTORC2 complex in C. elegans influ-
ences autophagosome biogenesis [43]. Since we also
found mTORC2 components coprecipitating with
PLEKHM1 (Fig. 1A,B), we cannot rule out a role for
mTORC2-mediated PLEKHM1 phosphorylation at
S432/S435. We additionally show that the very same
sites that are targeted by mTOR are also targets for the
MAPK pathway; hence, the inhibition of both MAPK
and mTOR results in a complete loss of phosphory-
lated PLEKHM1 at these sites. This indicates that
PLEKHM1 functions at the crossroads of these two
signalling pathways and potentially integrates them
into unique cellular response reflected in specific
dynamics of autophagosome-lysosome fusion (mTOR
pathway) or growth factor receptor degradation
(MAPK pathway), depending on cell type and func-
tion, as well as on physiological demands.
Regulation of adaptor and receptor proteins in both
autophagy and the endocytic pathway is an emerging
topic in how cells fine-tune their responses to stress,
and current data are highly supportive of phosphoryla-
tion as an important regulatory mechanism. For exam-
ple, during selective autophagy, the receptor proteins
optineurin and p62/SQSTM1 can both target ubiquiti-
nated Salmonella for destruction by the autophago-
some-to-lysosome pathway [44,45]. Interestingly, both
are phosphorylated by TBK1 to either enhance
MAP1LC3B interaction [45,46], enhance the interac-
tion with ubiquitinated Salmonella [47,48] or increased
activation of oxidative stress pathways [49]. This modi-
fiable switch helps in the mobilization and activation
of receptor activity, rendering it more effective in the
clearance of intracellular pathogens. In addition to
autophagy receptors, adaptor proteins that control for-
mation, trafficking and fusion of autophagosomes can
also be regulated in a similar manner. One such exam-
ple is protein Rubicon, which shares a high degree of
homology with PLEKHM1, is phosphorylated by
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HUNK at two serine residues in the region that binds
Vps34 and regulates the autophagy-suppressive func-
tion of Rubicon [50].
PLEKHM1 is phosphorylated at Ser432/Ser435
under normal growth conditions, but becomes rapidly
dephosphorylated under starvation conditions or upon
chemically induced inhibition of mTOR. As part of
our studies, we used doxycycline-inducible system for
the induction of overexpressed PLEKHM1. Although
we saw very little change in mTOR activity after doxy-
cycline addition, any potential metabolic changes
caused by the doxycycline may need to be explored in
future studies [51]. Potentially, there could be rapidly
acting phosphatases that change the dynamic pool of
phosphorylated PLEKHM1 that could affect the
dynamics of PLEKHM1-mediated fusion events in the
cells depending on the cellular demand. This pointed
towards high sensitivity of PLEKHM1 to the activity
of mTOR and physiological state of the cell.
In this study, our proteomics data correlates with pre-
vious reports of multiple deep-sequence mass spectrome-
try analyses (www.phosphosite.org). The phosphosites
are located within a highly conserved unstructured region
of PLEKHM1 and our data suggests an involvement of
major metabolic kinases in regulation of PLEKMH1
(Fig. 2H). In order to study this regulation in more
detail, we have developed several tools to study these
mechanisms, including a phospho-specific antibody that
detects a double-serine phosphorylation motif on
PLEKHM1 (S432/S435). In combination with CRISPR/
Cas9-mediated endogenous tagging of PLEKHM1 (Fig-
ure S1 and 1C), these tools will enable us to challenge the
cells with broader set of chemical compounds and
directly test both post-translational modifications, as well
as interacting partners of PLEKHM1 in a systematic
top-down approach. Further, combining such
approaches will allow us, and others, to accurately detect
and quantify levels and spatial organization of phospho-
rylated PLEKHM1 in various cell types and stress condi-
tions. This will help expand our understanding of the
interconnectivity between autophagy and growth factor
receptor signalling.
Similar to the examples of other autophagy adap-
tors, our data suggest that the function of phospho-
sites in PLEKHM1 could be regulation of interactions
of PLEKHM1 with components of the lysosome.
Under conditions of starvation or inhibition of
mTOR, mTOR dissociates from LAMP2-positive
structures, but PLEKHM1 remains associated
(Fig. 1E). Interestingly, mutation of PLEKHM1 at
Ser432/435 did not affect the known interaction
with GABARAP (Fig. S2A,B) [24,25,41] or Rab7
(Fig. S2C-D) [24,25,41] and so potentially does not
function in these distal interactions. However, we can-
not rule out any changes in the interaction with
HOPS/SNARE complex [26] or the recently identified
interaction with Arl8b that was mapped to the RUN
domain [27], which is in close proximity to phospho-
serine Ser432/Ser435 site. These phosphosites may,
therefore, act as on/off switch for PLEKHM1 function
during conditions such as cellular stress. In addition,
we also showed that these sites are not only a direct
target for mTOR, but that they also share similarities
with a MAPK PxSP motif and are sensitive to MAPK
inhibition alone. Indeed, phosphorylation of
PLEKHM1 at Ser432/Ser435 was induced by certain
growth factors via both MAPK-dependent (EGF,
FGF2, IGF-1) and MAPK-independent (PDGF-BB,
PDGF-AB) manner, indicating compartmentalization
of PLEKHM1 function. These data firmly position
PLEKHM1 regulation at the crossroads of two major
growth and proliferative signal transduction pathways
and, given our previous findings showing that
PLEKHM1 is required for both autophagosome and
EGFR degradation [26], our results shed some light on
possible mechanisms that may govern its activity.
These early findings will help pave a way to dissect
how these signalling pathways converge and regulate
the function of this adaptor protein at the molecular
level.
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Fig. S1. (A) U2OS cells modified using CRISPR/Cas9
plasmids showing parental (WT) PLEKHM1 KO and
GFP-tagged endogenous PLEKHM1. Total cell lysates
were probed with anti-PLEKHm1 and vinculin for
loading. (B) Mass spectra for PLEKHM1 phospho-
peptides that changed upon either starvation or 10 µM
Ku-0063794 and shown are shown for Ser432, Thr434
(C), Ser435 (D), Ser224 (E), Ser305 (F) and Ser501
(G).
Fig. S2. (A) HEK293T cells overexpressing HA-tagged
PLEKHM1 WT, PLEKHM1 S432A/S435A (2A) or
PLEKHM1 S432D/S435D (2D) were co-expressed
with either GFP alone or GFP-Rab7. Anti-GFP beads
were used to precipitate the GFP-tag and samples were
probed with ant-HA and anti-GFP antibodies. (B)
Quantification of (A) over n=3 independent experi-
ments shows no significant difference in the interaction
of PLEKHM1 with GFP-Rab7 using students t-test.
Mean  S.D shown. (C) HEK293T cells overexpress-
ing HA-tagged PLEKHM1 WT, -PLEKHM1-2A or
PLEKHM1-2D were co-expressed with either GFP
alone or GFP-GABARAP. Anti-GFP beads were used
to precipitate the GFP-tag and samples were probed
with ant-HA and anti-GFP antibodies. (D) Quantifica-
tion of (C) over n=3 independent experiments shows
no significant difference in the interaction of
PLEKHM1 with GFP-Rab7 using students t-test.
Mean  SD shown. (E) HEK293T cells transiently
overexpressing either empty vector HA-tagged
PLEKHM1 WT, PLEKHM1 S432A/S435A (2A) or
PLEKHM1 S432D/S435D (2D) were kept in either full
media (F) or treated with 200nM BafilomycinA1 (B)
or starved (S; EBSS media) for 2 hours. Cells were
lysed in total cell lysis buffer and subjected to SDS-
PAGE and western blot analysis. Membranes were
probed with anti-HA (PLEKHM1), anti-LC3B, anti-
p62/SQSTM1 and anti-vinculin as loading control. F.
Results from (E) were then quantified and fold change
of LC3B-II and p62 (G) were normalized to vinculin
loading. Shown is the mead  S.D. of n = 3 indepen-
dent experiments (represented by individual points) on
the scatter plots. Significance was calculated using one-
way ANOVA, but no significant differences were
observed between conditions.
Fig. S3. Quantification of phosphorylation of
PLEKHM1 under growth factor stimulation  torin1
or U0126 (related to Figure 4D). Fold change of
phospho-PLEKHM1 (S432/S435) normalized to total
PLEKHM1. Data represents mean  SEM of n = 3
independent biological repeats. Statistical significance
calculated using One-way ANOVA. * p = 0.0299 (NT
vs FGF2); p = 0.1083 (ns; NT vs FGF2+U0126); p =
0.0428; p = 0.0105 (FGF2 vs FGF2+U0126) ; p
=0.0146 (FGF2 vs FGF2 + torin1); p =0.0163 (FGF2
+ U0126 vs FGF2 + torin1).
Table S1. Plasmids used in this study.
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